A Glimmer of Hope for Immunotherapy in SCLC? A Glimmer of Hope for Immunotherapy in SCLC?
While combination immunotherapy did not show a survival benefit after chemoradiotherapy in small cell lung cancer, longer follow-up and biomarker analysis may reveal some gains, suggests trial data.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to results ...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to results ...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news
RethiNKing which immune cells are the best weapon against lung cancer
(Walter and Eliza Hall Institute) Immune cells called 'natural killer' (NK) cells could be a powerful weapon for fighting lung cancer, according to Melbourne researchers.Studying preclinical and patient samples of small cell lung cancer (SCLC), the Walter and Eliza Hall Institute team revealed that NK cells - but not T cells - are essential for slowing the aggressive spread of the cancer. 'Supercharging' the NK cells further boosted their cancer-fighting abilities. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 1, 2020 Category: Biology Source Type: news
Oncotarget: Correction of NSE concentration improves diagnostic accuracy in lung cancer
(Impact Journals LLC) Oncotarget Volume 11, Issue 27 published " Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer " by Genet et al. which reported that this study aimed to develop a hemolysis correction equation and evaluate its role in small-cell lung cancer (SCLC) diagnostics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news
Lurbinectedin (Zepzelca) Approved for Metastatic SCLC Lurbinectedin (Zepzelca) Approved for Metastatic SCLC
The FDA has granted accelerated approval for use of this new drug in metastatic small cell lung cancer (SCLC) that has progressed after or during treatment with platinum-based chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Up-Front Stereotactic Radiosurgery an Option for SCLC Brain Mets Up-Front Stereotactic Radiosurgery an Option for SCLC Brain Mets
The trade-offs with first-line SRS without WBRT include a shorter time to new brain metastases without an apparent difference in overall survival, according to the FIRE-SCLC study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Largest ever study of radiosurgery for brain metastases from small cell lung cancer
(University of Colorado Anschutz Medical Campus) The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology shows no overall survival benefit with whole-brain radiation therapy compared with radiosurgery in patients with small cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2020 Category: Cancer & Oncology Source Type: news
Medicaid Not Associated with Improved Survival in Patients with SCLC
These findings suggest that there are significant outcome inequalities for patients with small cell lung cancer which are relevant to the policy debate on Medicaid expansion under the Affordable Care Act. (Source: CancerNetwork)
Source: CancerNetwork - April 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Use of Prophylactic Cranial Irradiation in Patients with Limited Stage SCLC
Researchers found that using prophylactic cranial irradiation after thoracic radiation in patients with limited-stage small cell lung cancer undergoing contemporary head imaging is not associated with a decrease in risk of developing new brain metastasis. (Source: CancerNetwork)
Source: CancerNetwork - April 23, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer
30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 30, 2020 Category: Drugs & Pharmacology Source Type: news
FDA OKs Durvalumab Combo for Extensive-Stage SCLC FDA OKs Durvalumab Combo for Extensive-Stage SCLC
The immunotherapy is now approved for use in patients with small cell lung cancer (SCLC); it was already approved for non-small cell lung cancer (NSCLC).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 30, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Durvalumab Plus Standard of Care Chemo for Extensive-Stage SCLC
The FDA approved durvalumab (Imfinzi) as a first-line treatment for adult patients with extensive-stage small cell lung cancer in combination with standard-of-care chemotherapies, etoposide plus either carboplatin or cisplatin. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news
China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news
